\relax 
\providecommand\hyper@newdestlabel[2]{}
\providecommand\HyField@AuxAddToFields[1]{}
\providecommand\HyField@AuxAddToCoFields[2]{}
\providecommand\BKM@entry[2]{}
\BKM@entry{id=1,dest={73656374696F6E2A2E32},srcline={170}}{5C3337365C3337375C303030525C303030655C303030665C3030306C5C303030655C303030635C303030745C303030695C303030765C303030655C3030305C3034305C303030775C303030725C303030695C303030745C303030695C3030306E5C30303067}
\@writefile{toc}{\contentsline {section}{Reflective writing}{2}{section*.2}\protected@file@percent }
\newlabel{reflective-writing}{{}{2}{Reflective writing}{section*.2}{}}
\BKM@entry{id=2,dest={73656374696F6E2A2E33},srcline={237}}{5C3337365C3337375C303030425C303030615C303030635C3030306B5C303030675C303030725C3030306F5C303030755C3030306E5C303030645C3030305C3034305C3030306F5C3030306E5C3030305C3034305C303030655C303030615C303030725C3030306C5C303030795C3030305C3034305C303030645C303030655C303030745C303030655C303030635C303030745C303030695C3030306F5C3030306E5C3030305C3034305C3030306F5C303030665C3030305C3034305C303030635C303030615C3030306E5C303030635C303030655C30303072}
\citation{ref-hankey1999cancer}
\citation{ref-smith2002american}
\BKM@entry{id=3,dest={73656374696F6E2A2E34},srcline={259}}{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}
\BKM@entry{id=4,dest={73656374696F6E2A2E35},srcline={261}}{5C3337365C3337375C303030445C303030615C303030745C303030615C3030305C3034305C303030775C303030725C303030615C3030306E5C303030675C3030306C5C303030695C3030306E5C30303067}
\@writefile{toc}{\contentsline {section}{Background on early detection of cancer}{3}{section*.3}\protected@file@percent }
\newlabel{background-on-early-detection-of-cancer}{{}{3}{Background on early detection of cancer}{section*.3}{}}
\@writefile{toc}{\contentsline {section}{Global context of oncological screening of breast and cervical cancer}{3}{section*.4}\protected@file@percent }
\newlabel{global-context-of-oncological-screening-of-breast-and-cervical-cancer}{{}{3}{Global context of oncological screening of breast and cervical cancer}{section*.4}{}}
\@writefile{toc}{\contentsline {subsection}{Data wrangling}{3}{section*.5}\protected@file@percent }
\newlabel{data-wrangling}{{}{3}{Data wrangling}{section*.5}{}}
\BKM@entry{id=5,dest={73656374696F6E2A2E36},srcline={487}}{5C3337365C3337375C303030415C3030306E5C303030615C3030306C5C303030795C303030735C303030695C303030735C3030305C3034305C3030306F5C303030665C3030305C3034305C303030635C303030615C3030306E5C303030635C303030655C303030725C3030305C3034305C303030735C303030635C303030725C303030655C303030655C3030306E5C303030695C3030306E5C303030675C3030305C3034305C303030675C3030306C5C3030306F5C303030625C303030615C3030306C5C3030306C5C30303079}
\citation{ref-oecd-healthcareutilisation}
\citation{ref-oecd-cancercare}
\@writefile{toc}{\contentsline {subsection}{Analysis of cancer screening globally}{6}{section*.6}\protected@file@percent }
\newlabel{analysis-of-cancer-screening-globally}{{}{6}{Analysis of cancer screening globally}{section*.6}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {1}{\ignorespaces Trends in cancer screening worldwide. Temporal dynamics in the screening rate of cervical and breast malignant neplasms per country. Countries are straified according the data availability by 2000, if their screening rate was above 70\% (A-B), below 70\% (C-D), or data was not available (E-F). Segmented line represent a linear regression between time and screening percentage for each strata and neoplasm type. Data source: OECD.}}{7}{figure.caption.7}\protected@file@percent }
\providecommand*\caption@xref[2]{\@setref\relax\@undefined{#1}}
\newlabel{fig:fig1_print-oec-trends}{{1}{7}{Trends in cancer screening worldwide. Temporal dynamics in the screening rate of cervical and breast malignant neplasms per country. Countries are straified according the data availability by 2000, if their screening rate was above 70\% (A-B), below 70\% (C-D), or data was not available (E-F). Segmented line represent a linear regression between time and screening percentage for each strata and neoplasm type. Data source: OECD}{figure.caption.7}{}}
\BKM@entry{id=6,dest={73656374696F6E2A2E39},srcline={544}}{5C3337365C3337375C3030304C5C303030695C3030306D5C303030695C303030745C303030615C303030745C303030695C3030306F5C3030306E5C303030735C3030305C3034305C3030306F5C303030665C3030305C3034305C303030745C303030685C303030655C3030305C3034305C3030304F5C303030455C303030435C303030445C3030305C3034305C303030645C303030615C303030745C303030615C303030735C303030655C30303074}
\citation{ref-klabunde2015participation}
\citation{ref-bruni2022cervical}
\citation{ref-zhang2023canscreen5}
\BKM@entry{id=7,dest={73656374696F6E2A2E3130},srcline={571}}{5C3337365C3337375C3030304F5C3030306E5C303030635C3030306F5C3030306C5C3030306F5C303030675C303030695C303030635C303030615C3030306C5C3030305C3034305C303030735C303030635C303030725C303030655C303030655C3030306E5C303030695C3030306E5C303030675C3030305C3034305C303030695C3030306E5C3030305C3034305C303030535C303030635C3030306F5C303030745C3030306C5C303030615C3030306E5C30303064}
\BKM@entry{id=8,dest={73656374696F6E2A2E3131},srcline={573}}{5C3337365C3337375C303030445C303030615C303030745C303030615C3030305C3034305C303030775C303030725C303030615C3030306E5C303030675C3030306C5C303030695C3030306E5C30303067}
\@writefile{lof}{\contentsline {figure}{\numberline {2}{\ignorespaces Screening of malignant neoplasms of the breast. Target population: Female, 50-69 years old. (A-C) Temporal changes in the distribution of screening uptake for each 5-years period. (D) Association between screenning rate uptake and 5-years net survival. Source: OECD (https://data-explorer.oecd.org/).}}{8}{figure.caption.8}\protected@file@percent }
\newlabel{fig:fig2}{{2}{8}{Screening of malignant neoplasms of the breast. Target population: Female, 50-69 years old. (A-C) Temporal changes in the distribution of screening uptake for each 5-years period. (D) Association between screenning rate uptake and 5-years net survival. Source: OECD (https://data-explorer.oecd.org/)}{figure.caption.8}{}}
\@writefile{toc}{\contentsline {subsection}{Limitations of the OECD dataset}{8}{section*.9}\protected@file@percent }
\newlabel{limitations-of-the-oecd-dataset}{{}{8}{Limitations of the OECD dataset}{section*.9}{}}
\@writefile{toc}{\contentsline {section}{Oncological screening in Scotland}{8}{section*.10}\protected@file@percent }
\newlabel{oncological-screening-in-scotland}{{}{8}{Oncological screening in Scotland}{section*.10}{}}
\@writefile{toc}{\contentsline {subsection}{Data wrangling}{8}{section*.11}\protected@file@percent }
\newlabel{data-wrangling-1}{{}{8}{Data wrangling}{section*.11}{}}
\BKM@entry{id=9,dest={73656374696F6E2A2E3132},srcline={749}}{5C3337365C3337375C303030415C3030306E5C303030615C3030306C5C303030795C303030735C303030695C303030735C3030305C3034305C3030306F5C303030665C3030305C3034305C303030535C303030635C3030306F5C303030745C303030745C303030695C303030735C303030685C3030305C3034305C303030735C303030635C303030725C303030655C303030655C3030306E5C303030695C3030306E5C303030675C3030305C3034305C303030705C303030725C3030306F5C303030675C303030725C303030615C3030306D5C30303073}
\citation{ref-phs_scotdata}
\citation{ref-phs_scotdata}
\@writefile{toc}{\contentsline {subsection}{Analysis of Scottish screening programs}{11}{section*.12}\protected@file@percent }
\newlabel{analysis-of-scottish-screening-programs}{{}{11}{Analysis of Scottish screening programs}{section*.12}{}}
\citation{ref-kerr2024two}
\@writefile{lof}{\contentsline {figure}{\numberline {3}{\ignorespaces Screening of malignant neoplasms of the breast in Scotland. Health Board screening uptakes over three-year rolling period. Target population: Female, 50-70 years old. Horizontal line indicates target screening of 80\%. Data source: Public Health Scotland (https://publichealthscotland.scot/)}}{12}{figure.caption.13}\protected@file@percent }
\newlabel{fig:fig3_scot_screen_breast}{{3}{12}{Screening of malignant neoplasms of the breast in Scotland. Health Board screening uptakes over three-year rolling period. Target population: Female, 50-70 years old. Horizontal line indicates target screening of 80\%. Data source: Public Health Scotland (https://publichealthscotland.scot/)}{figure.caption.13}{}}
\BKM@entry{id=10,dest={73656374696F6E2A2E3135},srcline={810}}{5C3337365C3337375C303030525C303030655C303030635C3030306F5C3030306D5C3030306D5C303030655C3030306E5C303030645C303030615C303030745C303030695C3030306F5C3030306E5C303030735C3030305C3034305C303030615C303030685C303030655C303030615C303030645C3030305C3034305C303030695C3030306E5C3030305C3034305C303030745C303030685C303030655C3030305C3034305C303030635C3030306F5C3030306E5C303030745C303030655C303030785C303030745C3030305C3034305C3030306F5C303030665C3030305C3034305C303030745C303030685C303030655C3030305C3034305C303030525C303030655C303030735C303030655C303030615C303030725C303030635C303030685C3030305C3034305C303030615C3030306E5C303030645C3030305C3034305C303030495C3030306E5C3030306E5C3030306F5C303030765C303030615C303030745C303030695C3030306F5C3030306E5C3030305C3034305C303030535C303030745C303030725C303030615C303030745C303030655C303030675C30303079}
\@writefile{lof}{\contentsline {figure}{\numberline {4}{\ignorespaces Spatial heterogeneity of cancer mortality in Scotland. World age-standardised mortality rate (WASR) per 100,000 person-years at risk for period 2016-2020 across (A) all cancer types and (B) breast cancer by Health Board. Data source: Public Health Scotland (https://www.opendata.nhs.scot).}}{13}{figure.caption.14}\protected@file@percent }
\newlabel{fig:fig4_scot-maps}{{4}{13}{Spatial heterogeneity of cancer mortality in Scotland. World age-standardised mortality rate (WASR) per 100,000 person-years at risk for period 2016-2020 across (A) all cancer types and (B) breast cancer by Health Board. Data source: Public Health Scotland (https://www.opendata.nhs.scot)}{figure.caption.14}{}}
\@writefile{toc}{\contentsline {section}{Recommendations ahead in the context of the Research and Innovation Strategy}{13}{section*.15}\protected@file@percent }
\newlabel{recommendations-ahead-in-the-context-of-the-research-and-innovation-strategy}{{}{13}{Recommendations ahead in the context of the Research and Innovation Strategy}{section*.15}{}}
\BKM@entry{id=11,dest={73656374696F6E2A2E3136},srcline={840}}{5C3337365C3337375C303030525C303030655C303030665C303030655C303030725C303030655C3030306E5C303030635C303030655C30303073}
\bibcite{ref-bruni2022cervical}{\citeproctext }
\bibcite{ref-cedolini2014type}{\citeproctext }
\bibcite{ref-crosby2022early}{\citeproctext }
\bibcite{ref-hankey1999cancer}{\citeproctext }
\bibcite{ref-international2006survival}{\citeproctext }
\bibcite{ref-kerr2024two}{\citeproctext }
\bibcite{ref-klabunde2015participation}{\citeproctext }
\bibcite{ref-oecd-cancercare}{\citeproctext }
\bibcite{ref-oecd-healthcareutilisation}{\citeproctext }
\bibcite{ref-phs_scotdata}{\citeproctext }
\bibcite{ref-smith2002american}{\citeproctext }
\bibcite{ref-zhang2023canscreen5}{\citeproctext }
\newlabel{references}{{}{14}{References}{section*.16}{}}
\@writefile{toc}{\contentsline {section}{References}{14}{section*.16}\protected@file@percent }
\newlabel{refs}{{}{14}{References}{section*.17}{}}
\gdef \@abspage@last{14}
